We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RYEQO (Gedeon Richter Australia Pty Ltd)
Product name
RYEQO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
156 (255 working days)
Active ingredients
relugolix, norethisterone acetate, estradiol
Registration type
New combination
Indication
RYEQO is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.